|
Joint Committee and Joint Commission Meetings
|
Meeting/ Workshop
|
CDC, FDA, OS
|
NCI, FIC, NIAID
|
The US State Department establishes collaborative agreements with foreign governments in fields of science and technology. These Joint Committee and Joint Commission Meetings (JCMs) facilitate discussion on selected topics creating cross-talk among the equivalent government agencies leading towards future collaborations. The Office of Secretary (OS) of the Department of Health and Human Services (DHHS), through the Office of Global Affairs (OGA), organizes the operational divisions of HHS. The Fogarty International Center (FIC) facilitates the participation of National Institutes of Health (NIH) Institutes and Centers.
|
|
Joint External Evaluation Working Group (JEEWG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NCI, NIEHS, NINDS
|
Supports the Global Health Security Agenda activities related to International Health Regulations implementation to include internal and external joint evaluations, draft a National Action Plan (NAP) to address recommendations, and periodically review and report the status of the NAP.
|
|
Joint Fellowship Program
|
Training Initiative
|
FDA
|
NCI
|
The objective of the National Cancer Institute (NCI) and the Food and Drug Administration (FDA) Joint Fellowship Training Program is to train a cadre of scientists in research and research-related regulatory review, policies, and regulations so that they develop a skill set bridging the two disparate processes. Fellows learn to build awareness of regulatory requirements into the early stages of the medical product development process and develop strategies to improve planning throughout research and regulatory review.
|
|
Kaposi Sarcoma and HHV8 in Sickle Cell and Other Ugandan Populations
|
Research Initiative
|
CDC
|
NCI
|
Epidemiological studies are being conducted to assess small-area variation of Kaposi''s sarcoma-associated herpesvirus (HHV8) and to learn about socio-demographical and environmental risk factors for HHV8 and Kaposi sarcoma in Uganda.
|
|
Kidney Interagency Coordinating Committee
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS
|
NICHD, NIDDK
|
The Kidney Interagency Coordinating Committee (KICC) consists of Federal representatives involved in chronic kidney disease (CKD) programs and activities. KICC''s purpose is to encourage communication and collaboration to shape a more coordinated Federal response to CKD. Many Federal agencies lead an aspect of the multi-faceted and interconnected response to CKD.
|
|
Kidney, Urologic, & Hematologic Diseases Interagency Coordinating Committee
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS
|
NIDDK, NCCIH, NCI, NHLBI, NIA, NICHD, NINDS
|
The Kidney, Urologic, and Hematologic Diseases Interagency Coordinating Committee (KUHICC) encourages cooperation, communication, and collaboration among all Federal agencies involved in kidney, urology, and hematology research and other activities. Section 429 of Public Law 99-158 created the KUHICC in 1987. The committee met for the first time in 1988, and has the following subcommittees: Kidney Interagency Coordinating Committee, Urology Subcommittee, and Hematology Subcommittee. Meetings focus on interagency collaboration to elicit ideas from meeting participants to enhance current research directions within the National Institutes of Health and to form partnerships among agencies.
|
|
KidneyX (Kidney Innovation Accelerator)
|
Research Initiative
|
CMS, FDA
|
NIDDK
|
KidneyX, also called the Kidney Innovation Accelerator, is a public-private partnership between the U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN). Established in April 2018, KidneyX aims to use prize competitions to accelerate the development of innovative solutions that can prevent, diagnose, and/or treat kidney diseases. KidneyX aims to promote collaboration between patients, health professionals, innovators, industry, and government with the ultimate goal of improving quality of life for people living with kidney diseases.
|
|
Leprosy Research Support in Armadillos (Dasypus Novemcinctus)
|
Other
|
HRSA
|
NIAID
|
The Leprosy Research Support and Maintenance of an Armadillo Colony – Post Genome Era interagency agreement provides standardized research reagents to investigators worldwide to assist in the development of skin test antigens used to detect leprosy. This agreement supports collaborative research to continuously improve biochemical, microbiological, and immunological models for leprosy research in an effort to provide the most up-to-date resource and expertise for mycobacterial researchers.
|
|
Library of Integrated Network-based Cellular Signatures (LINCS)
|
Research Initiative
|
FDA
|
OD/DPCPSI/OSC, NHGRI, NHLBI
|
The Library of Integrated Network-based Cellular Signatures (LINCS) program is developing a library of data at the cellular level that describes how different types of cells respond to a variety of agents that disrupt normal cellular functions, called “perturbagens.” This library may help us better understand normal and diseased conditions in cells and how to alter them. The LINCS program engages with the Food and Drug Administration (FDA) regarding how LINCS data may be used to predict drug toxicity.
|
|
Logical Observation Identifiers Names and Codes (LOINC)
|
Resource Development
|
AHRQ, CDC, CMS, HRSA, IHS, OS
|
NLM
|
This activity supports the maintenance, distribution, and continued development of LOINC®, a set of universal codes and names to identify laboratory and other clinical observations which facilitates the exchange and pooling of clinical results for clinical care, outcomes management, public health, and research. The Regenstrief Institute, Inc., an internationally renowned healthcare and informatics research organization, maintains the LOINC database and supporting documentation, and the RELMA mapping program.
|